menu
    • menu

    Company profile for Vaxcyte

    NEW Drugs in Dev: 4
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal di...
    Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VaxcyteUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    825 Industrial Road, Suite 300 San Carlos, CA 94070
    Telephone
    Telephone
    (650) 837-0111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vaxcyte.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxcyte/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vaxcyte Reports 2025 Financial Results And Business Update
    Vaxcyte Reports 2025 Financial Results And Business Update

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3244031/0/en/Vaxcyte-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Vaxcyte Initiates OPUS-3 Ph 3 Trial For VAX-31 In Adults
    Vaxcyte Initiates OPUS-3 Ph 3 Trial For VAX-31 In Adults

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236651/0/en/Vaxcyte-Doses-First-Participants-in-OPUS-3-Phase-3-Trial-Evaluating-VAX-31-in-Adults-Previously-Vaccinated-with-Lower-Valency-Pneumococcal-Vaccines.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Vaxcyte To Present 2025 Financial Results & Business Update
    Vaxcyte To Present 2025 Financial Results & Business Update

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235769/0/en/Vaxcyte-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provide-Business-Update-on-February-24-2026.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Vaxcyte To Present At Guggenheim Emerging Outlook Biotech Summit
    Vaxcyte To Present At Guggenheim Emerging Outlook Biotech Summit

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233431/0/en/Vaxcyte-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Vaxcyte Closes $632.5M Offering on Underwriters' Full Exercise
    Vaxcyte Closes $632.5M Offering on Underwriters' Full Exercise

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230601/0/en/Vaxcyte-Announces-Closing-of-632-5-Million-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Vaxcyte Initiates Public Stock Offering And Pre-Funded Warrants
    Vaxcyte Initiates Public Stock Offering And Pre-Funded Warrants

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229102/0/en/Vaxcyte-Announces-Commencement-of-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search